A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Study Summary

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

Conditions

Primary Sclerosing Cholangitis

Interventions / Drugs

Volixibat Placebo

View on ClinicalTrials.gov ↗

Sponsor

MIRM

Mirum Pharmaceuticals

Liver Disease

D37/100

Study Details

Enrollment182 participants

Primary Completion—

Lead SponsorMirum Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:21:18.704660+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.